Drug Profile
AB 2004
Alternative Names: AB-2004Latest Information Update: 04 Oct 2023
Price :
$50
*
At a glance
- Originator California Institute of Technology/CalTech
- Developer Axial Therapeutics
- Class Behavioural disorder therapies; Neuroprotectants; Small molecules
- Mechanism of Action Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Pervasive child development disorders
Most Recent Events
- 26 Sep 2023 Axial Therapeutics completes enrolment in its phase IIb trial for Pervasive child development disorders in United States, Australia and New Zealand
- 05 Apr 2022 Updated pharmacodynamics data from preclinical studies in Pervasive child development disorders released by Axial Therapeutics
- 16 Feb 2022 Axial Biotherapeutics completes its phase I/II trial for Pervasive child development disorders in Australia and New Zealand (ACTRN12618001956291)